BioVie Inc. Warrant (BIVIW)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
BIVIW Chart
BioVie Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 500,000 | $128,550 | $254,999.99 | $126,449.99 | 98.37% |
 Leonid Berline ARMSTRONG ADVISORY GROUP Inc. | 65,900 | $23,065 | $32,950 | $9,885 | 42.86% |
BioVie Inc. Warrant (BIVIW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioVie Inc. Warrant ever had a stock split?
BioVie Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Mr. Cuong Viet Do M.B.A. CEO | NASDAQ (NMS) Exchange | - ISIN |
| US Country | 18 Employees | - Last Dividend | - Last Split | 5 May 2014 IPO Date |
Overview
BioVie Inc. stands as a pivotal entity in the biopharmaceutical sector, primarily focused on the exploration, development, and future commercial rollout of innovative medications designed to tackle chronic conditions debilitating individuals across the United States. The inception of BioVie traces back to its formation in 2013, originally established under the name NanoAntibiotics, Inc., before undergoing a transformative rebranding to its current identity in July 2016. With its corporate headquarters located in Carson City, Nevada, BioVie shoulders the mission of advancing therapeutic solutions into the healthcare marketplace, addressing the unmet medical needs of patients battling severe chronic disorders.
Products and Services
- BIV201
- NE3107
This lead compound from BioVie's pipeline has successfully maneuvered through a Phase IIa clinical trial, showcasing its potential as a promising therapeutic solution for patients suffering from ascites due to chronic liver cirrhosis. Ascites, a condition characterized by the abnormal accumulation of fluid in the abdomen, poses significant health risks and adversely affects the quality of life for individuals grappling with advanced liver disease. BIV201's development and clinical progression underscore BioVie's commitment to addressing the complex challenges faced by this patient population.
Rising as a potentially game-changing entity in the treatment landscape for neurodegenerative diseases, NE3107 inhibits the inflammatory extracellular signal-regulated kinase, a novel target offering therapeutic gains in inflammatory control. The drug is currently undergoing a Phase III clinical trial targeting patients with mild to moderate Alzheimer's disease, aiming to slow or halt the disease's progression. In parallel, NE3107 is also in a Phase 2 clinical trial for Parkinson's disease, indicating its versatile therapeutic potential across different neurodegenerative disorders. This marks a significant stride towards enriching the arsenal against these debilitating conditions, potentially improving life quality and outcomes for affected individuals.
